InMed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
IMLFF InMed Pharmaceuticals Inc
PNW Pinnacle West Capital Corp
AAPL Apple Inc
NAII Natural Alternatives International Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
VAL Valaris PLC
GE General Electric Co
XOM Exxon Mobil Corp
MSFT Microsoft Corp

Health Care : Biotechnology | Small Cap Growth
Based in CanadaCompany profile

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Closing Price
Day's Change
0.0234 (12.58%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

UPDATE: These 2019 stock market winners are your ticket to ride Wall Street's 'Big Mo' in December

10:22 am ET November 30, 2019 (MarketWatch)

By Mark Hulbert, MarketWatch

Momentum strategies typically are strongest in year-end trading

December is the best month in which to bet that the stock-market's winners will keep on winning. And for the losers to keep on losing.

I'm referring to the so-called momentum effect in the U.S. market, which is the tendency for the stocks that have performed the best over the trailing year to outperform those with the worst returns. While this effect is well-known on Wall Street, investors are less aware that it is most powerful in December.

Consider two portfolios, one equally divided among the 10% of stocks with the highest trailing returns (the "winners" portfolio) and the other containing the 10% of stocks with the worst (the "losers" portfolio). These portfolios are rebalanced monthly. Since 1926, according to data from Dartmouth University finance professor Kenneth French, this winners portfolio beat the losers portfolio by an average of 0.93% during the first 11 months of the year.

Not bad, but for the month of December, as you can see in the chart below, the outperformance of the winners is more than four times greater -- 3.82%. This difference is significant at the 95% confidence level that statisticians often use when determining whether a pattern is genuine.

What this means: Assuming the future echoes the past, you should favor the past year's best-performing stocks in any year-end trades. If you're making a longer-term bet on momentum strategies, you probably will want to place your bets now rather than wait until the New Year.

That's because, as the chart shows, January typically experiences a significant reversal of the momentum effect. Now it's the trailing year's worst performers to have their day in the sun, significantly outperforming the best performers.

Why would December exhibit such strong momentum effects, and January just the opposite? The answer, according to research conducted by Richard Sias (, chair of the finance department at the University of Arizona, traces to end-of-quarter "window dressing" and tax-loss selling.

Such strategic trading occurs when institutions (especially mutual funds) sell their losers towards the end of the year and buy more of their winning stocks -- in order to get bragging rights in year-end reports for having owned the winners, and to avoid the embarrassment of having invested in losing stocks. Tax-loss selling, meanwhile, occurs when investors sell the stocks they're holding at a loss in order to offset any capital gains on which they otherwise would have to pay tax.

Both factors cause buying in December to be concentrated on the recent past's winners and selling to be concentrated on the losers. In January, both of these factors are removed, and stocks correct for this artificial year-end pressure.

For the record, here are the stocks that are among the 10% of S&P 500 with the best year-to-date returns, and which are recommended by at least one of the top-performing newsletters I monitor:

-- Apple (AAPL)

-- Applied Materials (AMAT)

-- FleetCor Technologies (FLT)

-- General Electric (GE)

-- Lam Research (LRCX)

-- Masco (MAS)


-- Qorvo (QRVO)

-- Seagate Technology (STX)

-- Synchrony Financial (SYF)

-- Target (TGT)

-- Tyson Foods (TSN)

-- Western Union (WU)

Mark Hulbert is a regular contributor to MarketWatch. His Hulbert Ratings tracks investment newsletters that pay a flat fee to be audited. He can be reached at (

-Mark Hulbert; 415-439-6400;

RELATED: The 'great rotation' will arrive in 2020 and bring another strong year for stocks, JP Morgan says (

RELATED: Momentum stocks are down, but not for the reason you may have thought (

RELATED: 4 reasons why this bull market in stocks will keep going in 2020 (

(END) Dow Jones Newswires

November 30, 2019 10:22 ET (15:22 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.